Khosla Impact

Khosla Impact, established in 2013, is an impact investment firm based in Menlo Park, California. It focuses on assisting high-impact entrepreneurs who develop products and services for the three billion people at the bottom of the world's economic pyramid. The firm invests in for-profit enterprises serving low-income individuals and small businesses in emerging markets, with a primary focus on South Asia. Khosla Impact encourages experimentation and supports entrepreneurs passionate about solving socio-economic challenges through technology and innovative business models.

Alex Bentley

Partner and Investor

Ryno Blignaut

Operating Partner

Alice Brooks

Partner and Investor

Peter Buckland

COO, Partner, and Managing Director

Brian Byun

Operating Partner

Catherine Casuga

Operating Partner

Jonathan Chu

Partner and Investor

Ardy Daie

Operating Partner

Ece Erdagoz Wyrick

Principal and Investor

Kanu Gulati

Partner

Judy Huang

Operating Partner

Jun Jeon MD

Principal

Samir Kaul

Founding Partner and Managing Director

Vinod Khosla

Managing Director

Kelly Kinnard

Operating Partner

Nicholas Moryl

Associate

Keith Rabois

Managing Director

Arash Rebek

Partner, Capital Formation

Jessy Rivest

Partner and Investor

Jai Sajnani

Partner

Jai Sajnani

Partner and Investor

Leah Scanlan

Operating Partner

Nikita Shamgunov

Partner and Investor

Sven Strohband

Managing Director

Rajesh Swaminathan

Partner and Investor

Adina Tecklu

Partner and Investor

David Weiden

Managing Director

Reze Wong

Partner

Adam Coates

Operating Partner

Kanupriya Gulati Ph.D

Partner and Investor

Past deals in Healthcare

Science

Convertible Note in 2025
Science is a startup company that develops technologies for a range of serious unmet medical needs.

Tempero Bio

Series B in 2025
Tempero Bio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for treating and preventing substance use disorders. The company aims to address the challenges faced by individuals struggling with addiction, providing innovative treatments that facilitate recovery and improve overall health outcomes. By specializing in this critical area of healthcare, Tempero Bio seeks to make a meaningful impact on the lives of patients affected by substance use disorders and related conditions.

C the Signs

Venture Round in 2025
C the Signs is a cancer prediction system that empowers general practitioners to efficiently assess combinations of clinical signs, symptoms, and risk factors to identify patients at risk of cancer at its earliest and most treatable stages. The platform analyzes multiple diagnostic pathways, allowing physicians to make informed decisions during consultations, when the potential to influence patient outcomes is highest. By facilitating quick assessments, C the Signs enables doctors to recommend necessary investigations or urgent referrals in under 30 seconds, ultimately aiming to enhance early detection and improve survival rates for cancer patients.

Clear Labs

Series D in 2025
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive food analytics platform that utilizes next-generation sequencing and data analytics to enhance food safety and quality control. Its offerings include Clear Dx™ and Clear Safety™, which facilitate the rapid identification of pathogens and support public health initiatives. Clear Labs' platform delivers critical insights into the molecular composition of foods and ingredients, testing for authenticity, contaminants, allergens, and other safety parameters. By offering transparency across supply chains, the company serves food manufacturers, suppliers, and retailers, enabling them to improve operational efficiency and safety through detailed analytics and reporting.

Vitara Biomedical

Series B in 2024
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

HealthifyMe

Series D in 2024
HealthifyMe is a fitness application that supports users in achieving their health and weight loss objectives through digital platforms, including computers and smartphones. Launched in 2012 and based in Bangalore, India, the application allows users to track calories, nutrition, and fitness activities while monitoring their weight and overall health. It also enables users to set personalized health goals and access expert advice from nutritionists and fitness trainers. The platform features an artificial intelligence-powered fitness coach that uses automated analytics to help users manage their dietary intake and receive tailored online fitness consultations. Through its comprehensive tools and expert guidance, HealthifyMe aims to enhance individual wellness and promote healthier lifestyles.

Even

Series A in 2024
Even is a health tech company that provides comprehensive health coverage services through a subscription model. By partnering with leading hospitals, it offers unlimited access to diagnostics, consultations, and substantial hospitalization coverage for a fixed monthly fee. Even streamlines the healthcare experience with a claimless reimbursement process, directly transferring funds to partner hospitals on behalf of its members. This approach allows individuals to efficiently address their long-term health needs while simplifying the often complex healthcare payment process.

Synex Medical

Series A in 2024
Synex Medical is a company focused on advancing health monitoring technology through non-invasive blood testing. It has developed a portable device that utilizes a miniaturized magnetic resonance system to measure blood metabolites without the need for skin penetration. This innovative approach employs only magnets and radio waves, ensuring no adverse health effects for users. By accurately measuring critical metabolites such as glucose, lactate, and ketones, Synex Medical's technology empowers individuals to monitor their health proactively and make informed decisions about their well-being.

Neurode

Pre Seed Round in 2024
Neurode is a healthcare technology company developing a non-invasive wearable device, a headset, designed to enhance cognitive function for individuals with neurological conditions such as ADHD. The device aims to treat and monitor ADHD symptoms by employing non-invasive electrical stimulation to balance brain activity, while a paired app tracks improvements and facilitates communication with clinicians.

Inflammatix

Series E in 2024
Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Essor

Venture Round in 2024
Essor is a business that specializes in helping third-party seller brands from various marketplaces achieve global scale growth. It focuses on tasks such as acquisitions, investments, sourcing, and marketing. Essor's portfolio includes rapidly growing health and wellness, and lifestyle brands like Boka, ZitSticka, and Puracy, which are sold on platforms like Amazon, through direct-to-consumer channels, and in national retailers like Target and CVS. The company leverages technology, industry expertise, and strategic collaborations to transform these 'challenger' brands into globally recognized, omnichannel brands, ultimately delivering better value to customers and stakeholders.

Noetik

Series A in 2024
Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.

Openwater

Venture Round in 2024
Openwater is a medical technology startup founded in 2016 and based in San Francisco, California. The company specializes in developing advanced wearable devices that utilize novel optoelectronics to achieve MRI-like resolution for medical diagnostics and treatments. By employing LCDs with small pixels, Openwater's technology creates holographic images that reduce scattering, enabling physicians to visualize the inner workings of the body and brain at a cellular level. This innovation allows for precise diagnosis and targeted treatment of diseases by manipulating or destroying individual cells without damaging surrounding tissue. Openwater aims to revolutionize medical imaging and improve patient outcomes through its cutting-edge approach.

Even

Venture Round in 2024
Even is a health tech company that provides comprehensive health coverage services through a subscription model. By partnering with leading hospitals, it offers unlimited access to diagnostics, consultations, and substantial hospitalization coverage for a fixed monthly fee. Even streamlines the healthcare experience with a claimless reimbursement process, directly transferring funds to partner hospitals on behalf of its members. This approach allows individuals to efficiently address their long-term health needs while simplifying the often complex healthcare payment process.

Q Bio

Venture Round in 2024
Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Sword Health

Secondary Market in 2024
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Rubedo Life Sciences

Series A in 2024
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Nabla Bio

Series A in 2024
Nabla Bio is a biotechnology company that specializes in the development of an autoreverse platform for the discovery of innovative protein variants. These proteins, which exhibit unique qualities, are engineered to create new medicines and enhance nutritional products. By leveraging insights gained from billions of natural proteins, Nabla Bio enhances these variants through extensive experimentation, allowing for advanced applications in both medical and industrial fields. The company's focus on complex measurements of protein function positions it as a leader in the pursuit of previously unattainable protein capabilities.

Loyal

Series B in 2024
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the health span and lifespan of dogs. The company creates medicines designed to delay the onset of age-related diseases such as cancer, heart disease, and metabolic disorders. By quantifying and regulating the aging process, Loyal seeks to mitigate the effects of aging, thereby promoting healthier and longer lives for dogs. Through its innovative approach, the company aspires to improve the quality of life for pets and enhance their longevity.

Relation Therapeutics

Seed Round in 2024
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

CureSkin

Series B in 2024
CureSkin is a Bengaluru-based company founded in 2016 that specializes in AI-powered mobile applications for dermatological care. The application utilizes computer vision technology to analyze user-submitted photos, identifying various skin issues such as acne, dark spots, scars, and pigmentation. Based on this analysis, CureSkin recommends suitable products, personalized treatment plans, and connects users with dermatologists for follow-ups. By leveraging artificial intelligence, the company aims to provide accessible and tailored skin care solutions, allowing individuals to effectively manage their skin health without the need for in-person consultations with trained professionals.

Siolta Therapeutics

Series C in 2024
Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Limbic

Series A in 2024
Limbic is a London-based company founded in 2017 that specializes in developing innovative solutions for mental healthcare. The company creates an AI-enabled platform and software development kit (SDK) that measures heart rates through wearable devices, such as the Apple Watch, to assess users' emotional states. By leveraging machine learning, Limbic aims to enhance psychological therapy by providing insights into patients' mental health conditions. Additionally, the company offers medical devices that facilitate referrals and clinical assessments, thereby supporting mental health professionals in delivering effective therapies. Limbic is committed to addressing the growing mental health crisis by providing scalable solutions that improve the well-being of individuals.

TORTUS AI

Seed Round in 2024
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.

Moonwalk Biosciences

Series A in 2024
Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company specializes in creating a profiling and engineering technology platform that leverages advanced artificial intelligence predictions to offer a comprehensive view of the epigenome in both health and disease states. This innovative approach aims to revolutionize therapy discovery and development, enabling healthcare providers to reprogram cells back to their healthy state.

Encellin

Series A in 2023
Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.

Forward

Series E in 2023
Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

CellFE

Series A in 2023
CellFE Inc. is a biotechnology company based in San Carlos, California, established in 2017. It specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. This innovative platform enhances the manufacturing and development of cell therapies by utilizing rapid cell compression techniques that facilitate the uptake of therapeutic molecules from surrounding fluids. By enabling the transport of hard-to-deliver molecules, CellFE aims to improve the effectiveness of treatments for various disorders, supporting medical researchers in their efforts to advance patient care and outcomes.

Bold

Series A in 2023
Bold is an at-home digital fitness program designed to help older adults live their strongest, happiest, and healthiest lives. As a member, you’ll enjoy instant access to expert trainers, scientific assessments, and personalized workout plans to help you improve your strength, flexibility, and balance — so you can chase the life you want, at any age.

Rejuvenation Technologies

Seed Round in 2023
Rejuvenation Technologies Inc., established in 2016 and based in Mountain View, California, is a biotechnology company specializing in developing nucleoside-modified TERT mRNA. This technology safely and rapidly extends telomeres, enabling cells to proliferate more effectively. The company focuses on regenerative medicine applications, aiming to target age-related diseases and conditions across various organs such as the liver, lungs, and immune system. Their offerings include cell therapies like tissue engineering, transplants, skin grafts, immunotherapy, and regeneration medicine.

SiPhox Health

Series A in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

SiPhox Health

Seed Round in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Surge Therapeutics

Series B in 2023
SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.

Eureka Health

Seed Round in 2023
Helping people with chronic conditions mitigate their symptoms.

HealthifyMe

Series D in 2023
HealthifyMe is a fitness application that supports users in achieving their health and weight loss objectives through digital platforms, including computers and smartphones. Launched in 2012 and based in Bangalore, India, the application allows users to track calories, nutrition, and fitness activities while monitoring their weight and overall health. It also enables users to set personalized health goals and access expert advice from nutritionists and fitness trainers. The platform features an artificial intelligence-powered fitness coach that uses automated analytics to help users manage their dietary intake and receive tailored online fitness consultations. Through its comprehensive tools and expert guidance, HealthifyMe aims to enhance individual wellness and promote healthier lifestyles.

TORTUS AI

Seed Round in 2023
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.

Gather Health

Series A in 2023
Gather Health is an international healthcare technology company dedicated to empowering chronic disease patients to enhance their health. The company develops mobile and cloud-based healthcare applications that utilize cutting-edge medical and behavioral research to motivate and educate patients. By connecting physicians, patients, their families, and communities, Gather Health aims to provide continuous and holistic care that leads to improved health outcomes. The rise in chronic diseases such as obesity, diabetes, and hypertension has created a pressing need for effective patient care solutions, especially given the shortage of healthcare providers. Gather Health's flagship product, the Gather Health Diabetes platform, is currently utilized by physicians and patients in various cities across Hong Kong and India, including Mumbai and Bangalore, demonstrating positive health outcomes for users. Headquartered in Hong Kong, with additional offices in Beijing, New York, and India, the company boasts a diverse team of clinicians, health experts, interaction designers, and engineers experienced in the global healthcare landscape.

Tachyon

Series A in 2023
Tachyon Therapeutics is a biotechnology company focused on research and development aimed at creating innovative therapeutics for cancer treatment. The company is dedicated to developing first-in-class compounds that target new drug mechanisms in cancer biology, employing advanced techniques in molecular cancer biology, epigenetics, and cancer stem cell research. Currently, Tachyon is conducting Phase 1 clinical trials to evaluate the safety, pharmacokinetics, and anti-tumor effectiveness of its lead candidate, TACH101, in patients with advanced cancer. Through a commitment to high-quality and scientifically sound practices, Tachyon aims to provide novel treatment options that unlock new pathways for addressing complex cancer cases.

IgGenix

Series B in 2023
IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Even

Convertible Note in 2022
Even is a health tech company that provides comprehensive health coverage services through a subscription model. By partnering with leading hospitals, it offers unlimited access to diagnostics, consultations, and substantial hospitalization coverage for a fixed monthly fee. Even streamlines the healthcare experience with a claimless reimbursement process, directly transferring funds to partner hospitals on behalf of its members. This approach allows individuals to efficiently address their long-term health needs while simplifying the often complex healthcare payment process.

Surge Therapeutics

Series A in 2022
SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.

Ochre Bio

Series A in 2022
Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines specifically for transplanted livers and the treatment of fatty liver conditions. Founded in 2019 and based in Headington, United Kingdom, the company employs advanced genomic techniques to identify and inhibit overactive genes associated with liver diseases. This approach includes testing therapies in discarded donor livers that are maintained outside the body, ensuring that potential treatments can be evaluated in a relevant biological context. With over 15 years of expertise in liver genomics research, Ochre Bio aims to create a pipeline of innovative medicines that address liver and liver-mediated conditions, ultimately enhancing the availability of healthy livers for transplantation and reducing complications associated with cirrhosis. The company operates within Oxford's biotechnology innovation hub, leveraging its scientific foundation to advance therapeutic solutions in the field of liver health.

Proclaim

Series B in 2022
Fresh is a company that specializes in personalized oral care services and the development of solutions aimed at preventing oral diseases. Founded in 2017 by Mike Hanuschik and headquartered in Mountain View, California, Fresh focuses on addressing oral health issues that can lead to serious systemic diseases, such as diabetes, pancreatic cancer, Alzheimer’s, pneumonia, and heart disease. The company’s platform offers innovative remedies to improve oral health and ensure fresh breath for patients, contributing to overall well-being.

Vitara Biomedical

Series B in 2022
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Prellis Biologics

Series C in 2022
Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Faeth Therapeutics

Series A in 2022
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

CHARM Therapeutics

Series A in 2022
CHARM Therapeutics is a biotechnology company focused on delivering innovative medicines by leveraging advanced 3D deep learning and drug discovery technologies. Its platform is designed to address challenging disease targets that are typically considered undruggable, thereby enhancing treatment options for patients. By utilizing cutting-edge methodologies, CHARM Therapeutics aims to develop therapeutics with transformational efficacy, ultimately assisting healthcare professionals in improving patient outcomes.

Relation Therapeutics

Seed Round in 2022
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Mirvie

Series B in 2022
Mirvie is a biotechnology company specializing in non-invasive tests for maternal-fetal health, aimed at enhancing the safety of pregnancy. Founded in 2018 by Maneesh Jain and based in South San Francisco, California, Mirvie provides predictive diagnostic tools that deliver actionable insights to expectant mothers and families. Its medical diagnostic platform enables healthcare practitioners to identify at-risk pregnancies, facilitating timely interventions and therapeutic approaches to improve pregnancy outcomes. Through its innovative solutions, Mirvie seeks to empower families with critical information, ensuring a safer pregnancy experience.

Loop

Series B in 2022
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.

turn.bio

Venture Round in 2022
Turn.bio is a biotechnology company focused on developing innovative therapies aimed at reversing aging and age-related diseases. Leveraging a patented mRNA platform technology known as ERA, along with a specialized delivery system called eTurna, the company targets the epigenome to restore optimal gene expression. By designing tailored therapies, Turn.bio addresses a range of conditions, including immune-related diseases such as cancer, dermatological issues, and ailments in ophthalmology, osteoarthritis, and the muscular system. The company's approach involves inducing the body to heal itself by instructing specific cells to combat disease and repair damaged tissue, thereby reprogramming cellular functions to enhance health and longevity.

Scipher Medicine

Series D in 2022
Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Faeth Therapeutics

Seed Round in 2022
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Prellis Biologics

Series B in 2021
Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Robin Healthcare

Series B in 2021
Robin Healthcare, Inc. is a healthcare technology company founded in 2017 and headquartered in Berkeley, California, with an additional office in Austin, Texas. The company specializes in developing innovative solutions for the medical industry, including a smart assistant device, clinical documentation solutions, and services for order and medication entry, chart review, billing and coding, and referral management. Robin Healthcare provides comprehensive medical scribe services designed to alleviate administrative burdens on healthcare providers, thereby enhancing the doctor-patient experience. By integrating technology and trained medical scribes directly into electronic medical records, the company aims to streamline workflows and allow physicians to focus more on patient care.

Nabla Bio

Seed Round in 2021
Nabla Bio is a biotechnology company that specializes in the development of an autoreverse platform for the discovery of innovative protein variants. These proteins, which exhibit unique qualities, are engineered to create new medicines and enhance nutritional products. By leveraging insights gained from billions of natural proteins, Nabla Bio enhances these variants through extensive experimentation, allowing for advanced applications in both medical and industrial fields. The company's focus on complex measurements of protein function positions it as a leader in the pursuit of previously unattainable protein capabilities.

Sword Health

Series D in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Fountain Therapeutics

Series A in 2021
Fountain Therapeutics, established in 2018 and headquartered in San Francisco, specializes in developing treatments for age-related diseases using cellular models and an AI-based platform for target discovery. The company aims to recreate aging's complex hallmarks in lab dishes, combining this model with artificial intelligence and computer vision to identify novel targets unbiasedly.

Because Market

Series B in 2021
Because Market is a direct-to-consumer personal care company established in 2017, specializing in health and wellness products for older adults. The company aims to simplify the process for families to obtain essential products, including incontinence underwear and pads, skincare, supplements, and walkers. With a focus on discretion and convenience, Because Market offers its products through flexible subscription services, allowing families to ensure their senior members receive the care they need. The company's mission is to become the most trusted brand for older adults, supporting their ability to lead vibrant and independent lives.

Lightship

Series C in 2021
Lightship is a company founded in 2018 that focuses on transforming clinical trials to enhance health equity globally. By leveraging digital health innovations and remote care, it aims to make clinical research more accessible and patient-centered. Lightship provides decentralized and hybrid clinical services that improve patient experience, retention, and trial diversity. Its approach expands the pool of potential participants by moving beyond traditional research centers, effectively meeting patients in their own environments. This strategy helps to eliminate the barriers and inefficiencies associated with conventional clinical trial models, ultimately making medical research more inclusive and effective.

Loop

Series A in 2021
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.

Loyal

Series A in 2021
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the health span and lifespan of dogs. The company creates medicines designed to delay the onset of age-related diseases such as cancer, heart disease, and metabolic disorders. By quantifying and regulating the aging process, Loyal seeks to mitigate the effects of aging, thereby promoting healthier and longer lives for dogs. Through its innovative approach, the company aspires to improve the quality of life for pets and enhance their longevity.

Vicarious Surgical

Post in 2021
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company specializes in developing advanced technologies for minimally invasive surgical procedures, focusing on enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Its flagship product, the Vicarious Surgical Robotic System, integrates virtual reality software with human-like robotic capabilities, enabling surgeons to perform complex surgeries with greater precision and control. Designed for abdominal access through a single port, the system is compact and portable, facilitating easy integration into existing operating rooms. By minimizing invasiveness, Vicarious Surgical aims to accelerate patient recovery times and decrease post-operative discomfort, thereby transforming the landscape of surgical care.

House Rx

Seed Round in 2021
House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.

Eight Sleep

Series C in 2021
Eight Sleep, Inc. is a sleep technology company based in New York, focused on improving sleep quality through innovative smart mattresses and related accessories. Founded in 2014, the company manufactures products that include mattresses, sleep trackers, pillows, organic sheets, foundations, and various sleep-related items such as gravity blankets and blue wave glasses. Eight Sleep's mattresses are designed to regulate temperature, adjusting to the body's natural rhythms for optimal comfort, while also tracking health metrics to enhance sleep quality. The company emphasizes the importance of sleep for overall health and daily performance and sells its products primarily through online channels. Formerly known as Morphy, Inc., Eight Sleep has gained recognition as a leader in sleep technology and was honored as one of the Most Innovative Companies in Consumer Electronics by Fast Company in 2018.

Known Medicine

Seed Round in 2021
Known Medicine Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2020. The company specializes in developing a custom organoid platform designed for tumor sensitivity testing through advanced bioengineering techniques. Known Medicine focuses on transforming the process of evaluating how tumors respond to cancer therapies by taking tumor samples and breaking them down into microtumors. These microtumors are treated in specialized micro-environments using various methods to ascertain the most effective treatment options. The company's platform integrates machine learning with omics data to identify predictive biomarkers that inform oncologists about cancer cell behavior and potential treatment pathways, ultimately aiming to enhance personalized cancer care.

Flow Neuroscience

Series A in 2021
Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Encellin

Seed Round in 2021
Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.

Connie Health

Series A in 2021
Connie Health is a company focused on enhancing the healthcare decision-making process for older Americans, particularly those navigating Medicare. It provides medical advisory services designed to improve the customer experience in selecting and managing healthcare plans. Utilizing an AI-driven technology platform alongside local Medicare experts, Connie Health assists individuals in maximizing their insurance benefits, optimizing prescription costs, and locating healthcare providers in their vicinity. This comprehensive approach empowers seniors to make informed choices about their healthcare plans and effectively navigate their plan's benefits.

IgGenix

Series A in 2021
IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Even

Seed Round in 2021
Even is a health tech company that provides comprehensive health coverage services through a subscription model. By partnering with leading hospitals, it offers unlimited access to diagnostics, consultations, and substantial hospitalization coverage for a fixed monthly fee. Even streamlines the healthcare experience with a claimless reimbursement process, directly transferring funds to partner hospitals on behalf of its members. This approach allows individuals to efficiently address their long-term health needs while simplifying the often complex healthcare payment process.

HealthifyMe

Series C in 2021
HealthifyMe is a fitness application that supports users in achieving their health and weight loss objectives through digital platforms, including computers and smartphones. Launched in 2012 and based in Bangalore, India, the application allows users to track calories, nutrition, and fitness activities while monitoring their weight and overall health. It also enables users to set personalized health goals and access expert advice from nutritionists and fitness trainers. The platform features an artificial intelligence-powered fitness coach that uses automated analytics to help users manage their dietary intake and receive tailored online fitness consultations. Through its comprehensive tools and expert guidance, HealthifyMe aims to enhance individual wellness and promote healthier lifestyles.

Sword Health

Series C in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Ochre Bio

Seed Round in 2021
Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines specifically for transplanted livers and the treatment of fatty liver conditions. Founded in 2019 and based in Headington, United Kingdom, the company employs advanced genomic techniques to identify and inhibit overactive genes associated with liver diseases. This approach includes testing therapies in discarded donor livers that are maintained outside the body, ensuring that potential treatments can be evaluated in a relevant biological context. With over 15 years of expertise in liver genomics research, Ochre Bio aims to create a pipeline of innovative medicines that address liver and liver-mediated conditions, ultimately enhancing the availability of healthy livers for transplantation and reducing complications associated with cirrhosis. The company operates within Oxford's biotechnology innovation hub, leveraging its scientific foundation to advance therapeutic solutions in the field of liver health.

Ellipsis Health

Series A in 2021
Ellipsis Health, Inc. is a technology company based in San Francisco, California, founded in 2013. It specializes in developing innovative analytics solutions that integrate patient speech and clinical data to assess mental health and well-being. By utilizing artificial intelligence, Ellipsis Health aims to enhance behavioral health outcomes through the analysis of natural conversation. The company has created a platform that generates clinical-grade assessments of anxiety and depression severity, as well as sub-clinical evaluations of stress levels. This technology enables healthcare providers to continuously screen their patient populations, offering a cost-effective method to identify conditions such as depression and ensure patients receive timely support.

Clear Labs

Series C in 2021
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive food analytics platform that utilizes next-generation sequencing and data analytics to enhance food safety and quality control. Its offerings include Clear Dx™ and Clear Safety™, which facilitate the rapid identification of pathogens and support public health initiatives. Clear Labs' platform delivers critical insights into the molecular composition of foods and ingredients, testing for authenticity, contaminants, allergens, and other safety parameters. By offering transparency across supply chains, the company serves food manufacturers, suppliers, and retailers, enabling them to improve operational efficiency and safety through detailed analytics and reporting.

Hello Heart

Series C in 2021
Hello Heart Inc., established in 2013 and headquartered in Redwood City, California, specializes in developing digital health solutions. Its flagship product is Hello Heart, a mobile application designed to empower individuals to manage their heart health effectively. The app enables users to track their blood pressure and weight, providing real-time personalized tips based on clinical guidelines. Employers can also utilize this platform to proactively manage employee health risks associated with high blood pressure, fostering behavior change and preventing serious health issues.

Docbot

Series A in 2021
DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.

Apton Biosystems

Series A in 2021
Apton Biosystems, Inc. is a biotechnology company based in Pleasanton, California, founded in 2012. The company specializes in developing advanced optical systems for sequencing and protein detection, utilizing super-resolution technology to analyze molecules that are spaced closer than the wavelength of light. This innovative approach facilitates multi-omic sequencing and single-molecule protein detection, significantly enhancing capabilities in biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems aims to advance preventive health and precision medicine by addressing spatial challenges in high-density sequencing and protein analysis, thus contributing to improved healthcare outcomes.

turn.bio

Funding Round in 2021
Turn.bio is a biotechnology company focused on developing innovative therapies aimed at reversing aging and age-related diseases. Leveraging a patented mRNA platform technology known as ERA, along with a specialized delivery system called eTurna, the company targets the epigenome to restore optimal gene expression. By designing tailored therapies, Turn.bio addresses a range of conditions, including immune-related diseases such as cancer, dermatological issues, and ailments in ophthalmology, osteoarthritis, and the muscular system. The company's approach involves inducing the body to heal itself by instructing specific cells to combat disease and repair damaged tissue, thereby reprogramming cellular functions to enhance health and longevity.

Pendulum Therapeutics

Series C in 2021
Pendulum Therapeutics Inc., established in 2013 and headquartered in San Francisco, specializes in developing microbiome-targeted therapies for managing chronic illnesses, with a focus on type 2 diabetes. The company's flagship product, Pendulum Glucose Control, is a medical probiotic clinically proven to lower blood sugar spikes and reduce A1C levels. Pendulum Therapeutics uses evidence-based microbiome science and DNA sequencing, backed by a portfolio of patents and pending applications, to create targeted probiotics and prebiotics. The company sells its products online and has raised over $111 million in funding from prominent investors.

Quadrant Eye

Seed Round in 2021
Quadrant Eye is an innovative company focused on transforming the field of online eye care. It has developed a platform that facilitates instant and reliable remote eye examinations, allowing patients to screen, diagnose, and manage both low-acuity and chronic eye conditions from the comfort of their homes. The platform addresses a range of eye health issues, including cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy. By providing accessible services for conditions such as diabetic eye disease and nearsightedness, Quadrant Eye aims to enhance patient care and streamline the treatment process for various ocular health concerns.

StimScience

Seed Round in 2021
StimScience is a biotechnology company based in Berkeley, California, specializing in the commercialization of neuroscience and sleep research through innovative products and services. Founded in 2017, the company has assembled a team of experts, including esteemed scientists and professionals with backgrounds at Fitbit, Google, and Samsung, to address the critical issue of sleep health. StimScience develops advanced diagnostic and therapeutic solutions, such as Somnee, aimed at improving sleep quality and helping individuals achieve restorative rest. By leveraging their expertise in transcranial electrical stimulation (tES) technologies, including transcranial direct current stimulation and transcranial alternating current stimulation, they are equipped to tackle the widespread challenges associated with sleep disorders. Recognizing the importance of sleep for mental and physical health, StimScience seeks to contribute to a healthier society by enhancing sleep quality for individuals and addressing the growing sleep health epidemic.

Rightway

Series C in 2021
Rightway is a technology and services company focused on transforming the healthcare experience for clients and members. Specializing in care navigation and pharmacy benefit management (PBM) solutions, Rightway aims to reduce healthcare spending by guiding members to optimal care and therapies. The company's innovative approach incorporates clinical guidance and advocacy, ensuring that members receive the best possible healthcare at lower costs. Rightway’s modern care navigation technology offers efficient clinical support, while its unique PBM model drives prescriptions to the lowest net costs, minimizing overall expenses. By combining these services, Rightway strives to create a seamless and cost-effective healthcare journey for individuals and organizations alike.

Scipher Medicine

Series C in 2021
Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Inflammatix

Series D in 2021
Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Forward

Series D in 2021
Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

Bold

Seed Round in 2021
Bold is an at-home digital fitness program designed to help older adults live their strongest, happiest, and healthiest lives. As a member, you’ll enjoy instant access to expert trainers, scientific assessments, and personalized workout plans to help you improve your strength, flexibility, and balance — so you can chase the life you want, at any age.

Sword Health

Series B in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Ukko

Series B in 2021
Ukko is a biotechnology company focused on enhancing the quality of life for individuals affected by food allergies and disorders. The company utilizes a computational engineering platform that employs artificial intelligence, immunology, and protein engineering to redesign food allergens into therapeutics that are both safe and effective. By creating a comprehensive, clinically validated map of the molecular structures associated with food allergies, Ukko reveals critical insights into the biological mechanisms governing human-food interactions. This innovative approach enables the development of new protein versions that do not provoke an immune response, providing a novel strategy for treating protein-based allergies.

Lumiata

Series B in 2021
Lumiata Inc. is a company specializing in predictive health analytics tailored for risk-bearing organizations. Founded in 2013 and based in San Mateo, California, Lumiata utilizes a medical graph that systematically organizes and analyzes a vast array of data points, facilitating real-time predictive analytics for hospital networks and insurance carriers. This technology provides insights into symptoms, diagnoses, procedures, and medications, allowing healthcare providers to enhance patient care efficiency. The company's flagship product, The Lumiata Risk Matrix, offers personalized predictions regarding individual health changes and their timeline, grounded in a robust chain of medical reasoning. Lumiata's platform leverages over 120 million patient records, integrating advanced machine learning tools and pre-trained models to support various applications such as underwriting and care management. By combining big data with clinical expertise, Lumiata empowers healthcare organizations to manage risks and costs effectively while ensuring privacy for individual members.

Earli

Series A in 2021
Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.

Oscar Health

Venture Round in 2020
Oscar Health is a health insurance company based in New York, founded in 2012 by Joshua Kushner, Kevin Nazemi, and Mario Schlosser. It specializes in offering individual and family health insurance plans, Medicare Advantage programs for seniors, and small group products. Oscar Health aims to enhance the healthcare experience by leveraging technology, design, and data to make services more accessible and user-friendly. The company primarily serves individuals, couples, and families who do not receive employer-sponsored health insurance in select states, including New York, New Jersey, California, and Texas. In addition to traditional insurance offerings, Oscar provides virtual care, doctor support, and appointment scheduling, emphasizing a comprehensive approach to healthcare management.

Curai Health

Series B in 2020
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

Rubedo Life Sciences

Seed Round in 2020
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Advanced Chemotherapy Technologies

Series A in 2020
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.

Siolta Therapeutics

Series B in 2020
Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Invoy

Series A in 2020
Invoy is a company focused on enhancing health and weight loss outcomes through the integration of science, data, and artificial intelligence. It develops a monitoring medical device that offers personalized nutrition and wellness services by generating real-time data on an individual's metabolism. This device not only provides tailored, predictive nutrition recommendations but also features affordable breath analyzers for medical applications. By addressing the unique body chemistry of each individual, Invoy aims to empower users to achieve their specific health and wellness objectives.

Focal Medical

Series A in 2020
Focal Medical, Inc. is a privately held biopharmaceutical company headquartered in Cary, North Carolina, specializing in the development of innovative drug delivery systems for challenging cancers. The company focuses on creating novel therapeutic products that utilize a patented targeted therapeutic system, particularly for solid tumors that are difficult to treat with conventional systemic therapies. Its lead product delivers gemcitabine directly to the pancreas through non-circulatory pathways, specifically targeting pancreatic cancer. This approach combines iontophoresis drug delivery with an implantable system, allowing for precise drug administration akin to laser-like accuracy, which aims to enhance the efficacy of chemotherapy and facilitate quicker patient recovery. Formerly known as Advanced Chemotherapy Technologies, Inc., Focal Medical is dedicated to advancing treatments in genomic medicine and addressing unmet medical needs in oncology.

SiPhox Health

Seed Round in 2020
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.